PROPRANOLOL GENERIC SUBSTITUTIONS FOR INDERAL RE-INFARCTION INDICATION
PROPRANOLOL GENERIC SUBSTITUTIONS FOR INDERAL RE-INFARCTION INDICATION would not increase pharmacist liability risks, the California Pharmacists Assn. (CPhA) President John Berger declared in a recent news release. Responding to concern that pharmacists could face uninsured liability for dispensing generic propranolol for use by post-infarction patients, CPhA President Berger said: "Drugs which are lawfully on the market, approved for one indication, may be lawfully prescribed for other unapproved indications." Berger noted that "Inderal, in fact, was used for a number of years in the successful treatment of post-MI patients before the FDA granted it an approved labelling indication for that purpose." Berger's letter responds directly to a "generic alert" letter sent to pharmacists in California by a group called the Pharmacists Planning Service, Inc. (PPSI). Pointing out the exclusive myocardial infarction for Inderal, PPSI maintained: "You, the pharmacist, may be at risk by dispensing a generic product if the branded product has been prescribed." The threat of uninsured liability from propranolol substitution "is false," CPhA said. The assn. president called the claim "the worst kind of professional scare tactic." Berger said: "Pharmacists should not be misled by this blatant misconstruction of the law." The CPhA president said: "A pharmacist may legally dispense a brand other than the one prescribed if the drug is the same generic drug type and the same dosage form and strength, unless the physician specifically prohibits use of a generic." Berger added that the pharmacist is not required to check on the diagnosis behind an Rx. "In fact," he said, "there is no requirement that the physician or the patient inform the "pharmacist of the diagnosis even if it is requested." Ayerst will inform MDs of the exclusive Inderal indication, Berger contended. "If the cardiologist is concerned that other propranolols may be less safe or effective, he or she may foreclose brand interchange by an indication on the Rx," Berger said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth